Severe thrombocytopenia refractory to platelet transfusions, secondary to abciximab readministration, in a patient previously diagnosed with idiopathic thrombocytopenic purpura. A possible etiopathogenic link;Trombocitopenia severa, persistente a transfusiones plaquetarias, secundaria a readministración de abciximab en paciente con antecedentes de púrpura trombocitopénica idiopá tica. Un posible nexo etiopatogénico

Revista Espanola de Cardiologia

Volumn 57, Issue 8, 2004, Pages 789-791

  Méndez, Tomś C ^a   Díaz, Oscar ^a   Enríquez, Lourdes ^a   Baz, José A ^a   Fernández, Felipe ^b   Goicolea, Javier ^a  

^a HOSPITAL DO MEIXOEIRO   (Spain)

^b HOSPITAL DE LEÓN   (Spain)

Author keywords

Glycoprotein IIb IIIa; Platelets; Thrombocytopenia

Indexed keywords

ABCIXIMAB; IMMUNOGLOBULIN G;

AGED; ARTICLE; CASE REPORT; DISEASE SEVERITY; HEART MUSCLE REVASCULARIZATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; MEDICAL DOCUMENTATION; MEDICAL RECORD; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; REFRACTORY THROMBOCYTOPENIA; SURGICAL TECHNIQUE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 4744374101     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13064833     Document Type: Article

References (9)

1. Ibbotson T, Mcgavin JK, Goa KL. Abciximab. An update review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularization. Drugs 2003; 63:1121-63.
2. The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
3. The EPISTENT investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
4. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997;95:809-13.
5. Schell DA, Ganti AK, Potti A. Trombocytopenia associated with C7E3 fab (abciximab). Ann Hematol 2002;81:76-9.
6. Kereiakes DJ, Essell JH, Abbottsmith CW, Broderick TM, Runyon JP. Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion. Am J Cardiol 1996;78:1161-3.
7. Tcheng JE, Kereiakes DJ, Lincoff AM, George BS, Kleiman NS, Sane DC, et al. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 2001;104:870-5.
8. Boughton BJ, Cooke RM, Smith NA, Simpson AW. Autoinmune thrombocytopenia: anti-glycoprotein IIb/IIIa auto antibodies are reduced after human anti-d inmunoglobulin treatment. Autoinmunity 1994;18:141-4.
9. Peter K, Straub A, Kohler B, Volkmann M, Schwarz M, Kubler W, et al. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia. Am J Cardiol 1999;84:529-4.